PharmaJet and Abnova to Jointly Develop and Deliver COVID-19 mRNA Vaccine Using Needle-Free Injection Technology

Abnova's DNAx Immune technology enables the rapid production of highly sensitive and specific antibodies for research, in vitro diagnostics, and therapeutic antibody applications. By leveraging the DNAx gene sequence antibody response bioinformatics, Abnova is accelerating the development of mRNA vaccines targeting infectious diseases and cancers. It has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of its mRNA candidate.

"We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx Immune platform," said Dr. Wilber Huang, President and CEO, Abnova. "We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome."

"We are pleased to be collaborating with Abnova on the development of their SARS-CoV-2 mRNA vaccine," commented Chris Cappello, President and CEO, PharmaJet, "Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings."

Related Links:
PharmaJet
Abnova